Roadmap of HIV/TB Sessions

**SUNDAY, 19 JULY 2015**

**Testing, New Directions in Treatment, and Measuring Impact: New WHO Guidelines**
Non-Commercial Satellite – SUSA06
Time: 12:30 - 14:30 Venue: Room 211-214
Organizers: World Health Organization
This satellite will launch the new 2015 WHO consolidated guidelines on HIV testing services (HTS), share new directions and evidence that will shape the 2015 update to the WHO Consolidated guidelines on the use of ARV drugs for treating and preventing HIV, and present the newly released 2015 WHO Consolidated strategic information guidelines for HIV in the health sector.

**MONDAY, 20 JULY 2015**

**Global Research Capacity Building for HIV Clinical Pharmacology and Therapeutics Implementation**
Non-Commercial Satellite – MOSA02
Time: 07:00 - 08:30 Venue: Room 109
Organizers: University at Buffalo, State University of New York, University of Zimbabwe
This satellite will focus on novel aspects that integrate clinical pharmacology research including clinically important pharmacokinetic drug interactions (e.g. anti-tuberculosis drugs).

**HIV and TB: Gaps and Opportunities**
Oral Abstract Session Track B – MOAB02
Time: 11:00 – 12:40 Venue: Ballroom C-D
Co-Chairs: C Benson, USA, H Getahun, WHO, Switzerland
11:00 MOAB0201: The durability of isoniazid preventive therapy for TB: long-term follow-up from a prospective cohort of HIV-infected adults in South Africa. Presenter: C Hanrahan, USA
11:15 MOAB0202: Treatment outcomes of drug-resistant TB patients in South Africa, disaggregated by HIV status, as reported in a national electronic drug-resistant TB register. Presenter: E Budgell, South Africa
11:30 MOAB0203: Excess TB mortality in HIV patients in Eastern Europe: restructured approach to care needed. Presenter: A Schultz, UK
12:00 MOAB0205LB: Empiric TB therapy does not decrease early mortality compared to isoniazid preventive therapy in adults with advanced HIV initiating ART: results of ACTG A5274 (REMEMBER study). Presenter: M Hosseinipour, Malawi
12:15 IAS TB/HIV Research Prize

Non-Commercial Satellite – MOSA04
Time: 18:30 - 20:30 Venue: Room 121-122
Organizer: WHO and UNAIDS
This session presents an overview of the WHO consolidated guidelines on HIV Testing Services and the revised guidance on national population-based HIV surveys and how both guidelines can support progress towards reaching the UNAIDS’ 90-90-90 targets by 2020.

**TUESDAY, 21 JULY 2015**

**AIDS for Global Health: How can the HIV Response Inform Advances in Global Health?**
Symposia Session: TUSY03
Time: 16:30 – 18:00 Venue: Room 211-214
Co-Chairs: R Horton, UK and S A Karim, South Africa
17:00 TUSY0304: Best practices in integrated research and programmes: achieving HIV and primary care synergies. Presenter: D Havlir, USA
TUESDAY, 21 JULY Continued

**Achieving 90:90:90: New clinical, Operational and Policy Guidance**

Symposia Session: TUSY04  
Time: 16:30 – 18:00  
Venue: Room 118-120  
Co-Chairs: Y Pillay, South Africa and W El Sadr, USA

This session provides an update on global policy, normative and operational guidance to help countries strengthen their HIV testing and offer continuum of care to achieve 90-90-90 targets.

WEDNESDAY, 22 JULY 2015

**Immunity and immunization**

Oral Abstract Session Track A - WEAA01  
Time: 14:30 - 16:00  
Venue: Ballroom C-D  
Co-Chairs: J Scott, Canada and J Mann, Canada

15:45 WEAA0106LB: The potential of attenuated *Mycobacterium tuberculosis* or BCG vaccines to enhance oral SIV acquisition in infant macaques. Presenter: K De Paris, USA

**Poster Exhibition (Monday)**

MOPEB159: CYP2B6 genotype based efavirenz dose recommendations during rifampicin based anti-tuberculosis treatment for a sub-Saharan Africa population. Presenter: J Mukonzo, Uganda


MOPEB162: Population-based, active TB case finding during large scale, mobile HIV testing campaigns in rural Uganda. Presenter: E Ssemmanda, Uganda

MOPEB163: Is prophylaxis against tuberculosis required for HIV-infected individuals in low incidence settings? Presenter: K Manavi, UK


MOPEB166: Prognostic indicators for severely ill HIV-infected patients with suspected tuberculosis. Presenter: R Griesel, South Africa

MOPEB167: Performance of latent TB infection diagnostics in HIV-infected pregnant women in western Kenya. Presenter: S LaCourse, USA

MOPEB189: Integration of TB screening in Kenyan PMTCT programs. Presenter: L Cranmer, USA

MOPEB749: Linkage to TB treatment in Botswana among Tebelopele clients who screened positive for TB, 2008-2012. Presenter: N P Menezes, USA

**Poster Exhibition (Tuesday)**

TUPEB235: Global performance of GeneXpert (Xpert MTB/RIF, Cepheid) using standardized verification and external quality assessment material, presented by L Scott, South Africa

TUPEB276: Rifabutin for treating tuberculosis in HIV-infected adult patients receiving boosted protease inhibitor containing ART regimen: experiences of neutropenia from an urban clinic. Presenter: T Mudzviti, Zimbabwe

TUPED761: Effective use of task shifting in strengthening 4 symptom screening for TB disease among PLHIV in rural clinics in Northern Nigeria. Presenter: G Egesimba, Nigeria

TUPED762: Integrating direct provision of ART into TB services to increase ART uptake among TB-HIV co-infected clients in south west Uganda (2010-2014). Presenter: E Natumanya Kajungu, Uganda

TUPED794: Engaging the community to improve delivery and uptake of TB HIV collaborative services at health facilities: experience from public health facilities in Northern Nigeria. Presenter: A Inedu, Nigeria

TUPED808: Who doesn’t disclose their HIV-positive status? Patterns of disclosure and factors associated with not disclosing to a spouse or primary sexual partner among TB-HIV patients initiating antiretroviral therapy in Lesotho. Presenter: E Hayes-Larson, USA

TUPED816: Accelerated HIV/TB service integration into primary care clinics and programmatic outcomes in rural Swaziland. Presenter: B Kerscherberger, Swaziland

TUPED828: Community-led integrated service delivery “war rooms” game changing the fight against HIV/AIDS and TB: case study of the Operation Sukuma Sakhe model in KwaZulu-Natal, South Africa. Presenter: N Ndlovu, South Africa

**Poster Exhibition (Wednesday)**

WEPEA132: Dynamic imaging of intracellular glutathione redox potential of HIV-1 infected macrophages and its exploitation of *Mycobacterium tuberculosis* through its lipids. Presenter: M Munshi, India

WEPED901: m-Health: intervention to rapidly link Xpert MTB/RIF rifampicin resistant patients to treatment initiation in South Africa. Presenter: L Stewart-Isherwood, South Africa